Patents by Inventor Kurt Hilpert

Kurt Hilpert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8273740
    Abstract: The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent “chemoattractant receptor-homologous molecule expressed on Th2 cells” antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.
    Type: Grant
    Filed: August 23, 2005
    Date of Patent: September 25, 2012
    Assignee: Actelion Pharmaceuticals, Ltd.
    Inventors: Heinz Fretz, Markus Gude, Kurt Hilpert, Julien Pothier, Markus Riederer, Matthias Steger
  • Patent number: 8202885
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: June 19, 2012
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg
  • Publication number: 20120053149
    Abstract: The present invention relates to thiazole derivatives of formula I and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
    Type: Application
    Filed: April 21, 2010
    Publication date: March 1, 2012
    Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, David Lehmann, Emmanuel Meyer, Dorte Renneberg
  • Publication number: 20120028989
    Abstract: The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
    Type: Application
    Filed: April 7, 2010
    Publication date: February 2, 2012
    Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, Emmanuel Meyer, Dorte Renneberg
  • Patent number: 8093250
    Abstract: The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: January 10, 2012
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Eva Caroff, Kurt Hilpert, Emmanuel Meyers
  • Patent number: 8058263
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: November 15, 2011
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, Emmanuel Meyer, Dorte Renneberg
  • Patent number: 8048881
    Abstract: The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: November 1, 2011
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Eva Caroff, Heinz Fretz, Kurt Hilpert, Olivier Houille, Francis Hubler, Emmanuel Meyer
  • Publication number: 20110263667
    Abstract: The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.
    Type: Application
    Filed: October 21, 2009
    Publication date: October 27, 2011
    Inventors: Stefan Abele, Stéphanie Combes, Jacques-Alexis Funel, Kurt Hilpert, Francis Hubler, Katharina Reichenbaecher, Dorte Renneberg, Markus Von Raumer
  • Publication number: 20110263648
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
    Type: Application
    Filed: October 21, 2009
    Publication date: October 27, 2011
    Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg
  • Patent number: 8044055
    Abstract: The invention relates to 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. Formula (I).
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: October 25, 2011
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Eva Caroff, Kurt Hilpert, Emmanuel Meyer
  • Publication number: 20110207815
    Abstract: The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4, R5, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 25, 2011
    Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg
  • Patent number: 7897788
    Abstract: The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: March 1, 2011
    Assignee: Actelion Pharmaceutical Ltd.
    Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
  • Publication number: 20110046089
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
    Type: Application
    Filed: April 9, 2009
    Publication date: February 24, 2011
    Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, Emmanuel Meyer, Dorte Renneberg
  • Publication number: 20110039905
    Abstract: The invention relates to compounds of formula (I) wherein R1 represents aryl, which is unsubstituted, or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, and trifluoromethyl; R2 represents hydrogen, or —CO—R21; R21 represents (C1-5)alkyl, (C1-3)fluoroalkyl, or (C3-6)cycloalkyl; m represents the integer 2, or 3; p represents the integer 2 or 3; and R3 represents hydrogen, or (C1-5)alkyl; and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
    Type: Application
    Filed: April 23, 2009
    Publication date: February 17, 2011
    Inventors: Francis Hubler, Kurt Hilpert, Dorte Renneberg
  • Publication number: 20100261678
    Abstract: The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).
    Type: Application
    Filed: November 28, 2008
    Publication date: October 14, 2010
    Inventors: Eva Caroff, Kurt Hilpert, Francis Hubler, Emmanuel Meyer, Dorte Renneberg
  • Publication number: 20100234396
    Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.
    Type: Application
    Filed: March 16, 2010
    Publication date: September 16, 2010
    Applicant: Actelion Pharmaceuticals Ltd
    Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
  • Patent number: 7727979
    Abstract: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R?)— or —O— and R? is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: June 1, 2010
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Eva Caroff, Matthias Steger, Oliver Valdenaire, Anja Fecher, Volker Breu, Kurt Hilpert, Heinz Fretz, Thomas Giller
  • Publication number: 20100130545
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.
    Type: Application
    Filed: April 25, 2008
    Publication date: May 27, 2010
    Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg
  • Patent number: 7714132
    Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: May 11, 2010
    Assignee: Actelion Pharmaceuticals, Ltd.
    Inventors: Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
  • Publication number: 20100035895
    Abstract: The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis.
    Type: Application
    Filed: October 12, 2007
    Publication date: February 11, 2010
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Eva Caroff, Kurt Hilpert, Emmanuel Meyers